Vitamin K2 is now recognized as an essential ingredient for aging healthily. This understanding stems from the substantial body of clinical evidence confirming the bone and cardiovascular health benefits of Vitamin K2 as MK-7 started by NattoPharma and is now being perpetuated by Gnosis by Lesaffre. Securing and maintaining our bone and cardiovascular health are two of the most significant areas impacting our ability to age well. Both areas are impacted by the way our bodies utilize calcium. Ideally, calcium would bind to the bone matrix, shoring our skeletal health. But this is not always the case, particularly if we are not obtaining enough Vitamin K2 as MK-7 from either our diets or supplementation. Vitamin K2 as MK-7 helps the body properly utilize calcium by activating vitamin K-dependent proteins already present in the body: • Osteocalcin, once activated by K2, binds calcium to the bone mineral matrix (where it is needed) • Matrix Gla Protein (MGP), once activated by K2, inhibits calcium from depositing in arteries and soft tissues (where it can cause harm) Yet this is just the tip of the iceberg. New research is coming to light connecting the already established Vitamin K2 as MK-7 mechanism to other areas of health, including brain, vision, and more. The Most Comprehensive Vitamin K2 Offer Once Gnosis by Lesaffre acquired NattoPharma in 2021, the company could unequivocally state that it offered the most comprehensive Vitamin K2 portfolio on the market. It now offers customers, • MenaQ7® - the best clinically validated K2 as MK-7 on the market, as it was the source material used in more than 22 human clinical trials confirming safe and efficacious health benefits. Further, MenaQ7 is the only K2 as MK-7 patented for cardiovascular health. • vitaMK7® - naturally produced from a patented biofermentation process, the line has recently been enhanced by introducing the Matrix protective technology.